Cuban-French Collaboration Starts to Bear Fruit
The newly formed ABIVAX is now working with the Cuban Center for Genetic Engineering and Biotechnology to develop therapeutic vaccines and antivirals.
In what is claimed to be the first ever start-up launched on the basis of a European-Cuban R&D alliance, the newly formed ABIVAX (based in Paris, France) is now working with the Cuban Center for Genetic Engineering and Biotechnology (Centro de Ingenieria Genética y Biotecnologia, CIGB) to develop therapeutic vaccines and antivirals.
ABIVAX combines the technologies and the product portfolios of three French biotech companies financed by Truffle Capital (Wittycell, Splicos, and Zophis). The Cuban government has approved a partnership agreement with the CIGB, which is the largest among the dozen or so subsidiaries under BioCubaFarma that specialize in the discovery, development and production of vaccines and antivirals.
“We are proud to have founded ABIVAX after two years of discussion with Cuba, which is known for its excellent physicians and high-quality vaccines,” said Philippe Pouletty, MD, founder and Chairman of ABIVAX. “ABIVAX is the first biopharma company to have established a major collaboration with Cuba. This is an international project that is intended to place France and Cuba at the forefront of progress in the field of therapeutic vaccines.”
Among the products in development are a therapeutic vaccine for chronic hepatitis B from CIGB and Wittycell; a novel anti-viral drug for AIDS from Splicos; an anti- human papilloma virus (HPV) therapeutic vaccine to treat, without surgery, uterine cervix dysplasia and prevent the emergence of cancer from Wittycell; and a novel adjuvant to boost natural killer T (NKT) and B cell response from Wittycell.
ABIVAX has two therapeutic vaccines in development: one in a Phase IIb clinical trial in patients with chronic hepatitis B, and the other one expected to enter into a Phase I clinical trial in 2015 for the treatment of chronic infection with HPV and cervical dysplasia (an early stage in cervical cancer). The adjuvant is in Phase I clinical studies. In the field of AIDS, the company's first antiviral drug is scheduled to enter clinical trials in Q1 2014. Additional therapeutic vaccines are in preclinical development.
Empowering Sites and Patients: The Impact of Personalized Support in Clinical Trials
November 26th 2024To meet the growing demands of clinical research, sponsors must prioritize comprehensive support models, such as clinical site ambassadors and patient journey coordinators, who can address operational challenges and improve site relationships, patient satisfaction, and overall trial efficiency.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
FDA Finalizes Decentralized Clinical Trial Guidance
November 25th 2024The FDA's guidance is part of a broader effort to modernize clinical trials, improve efficiency, reduce participant burden, and expand access, particularly for underrepresented populations and those in geographically or economically constrained areas.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
